Praxis Precision Medicines (PRAX) Income from Continuing Operations (2019 - 2026)
Praxis Precision Medicines (PRAX) recorded quarterly Income from Continuing Operations of 105860000.0 in Q1 2026, down 9.08% quarter-over-quarter from 97044000.0 in Q4 2025, and down 41.66% on a YoY basis from 181454860.08 in Q1 2025.
Praxis Precision Medicines (PRAX) Income from Continuing Operations (2019 - 2026) Analysis & Trends
Praxis Precision Medicines' Income from Continuing Operations history runs 8 years deep, the most recent figure standing at 105860000.0 for Q1 2026.
- In Q1 2026, Income from Continuing Operations fell 41.66% year-over-year to 105860000.0; the TTM figure through Mar 2026 stood at 357330000.0 (down 53.36% YoY), while the FY2025 annual figure was 326198000.0, down 62.96% from the prior year.
- Income from Continuing Operations was 105860000.0 for Q1 2026 at Praxis Precision Medicines, down from 97044000.0 in the prior quarter.
- In the past five years, Income from Continuing Operations ranged from a high of 25516000.0 in Q3 2023 to a low of 105860000.0 in Q1 2026.
- Historically, Income from Continuing Operations has averaged 57249235.29 across 5 years, with a median of 56835000.0 in 2024.
- The sharpest annual moves came in 2022 and 2023: Income from Continuing Operations sank 151.52% in 2022, then soared 44.67% in 2023.
- A 5-year view of Income from Continuing Operations shows it stood at 41453000.0 in 2022, then soared by 32.92% to 27806000.0 in 2023, then tumbled by 130.01% to 63956000.0 in 2024, then plunged by 51.74% to 97044000.0 in 2025, then fell by 9.08% to 105860000.0 in 2026.
- The last three Income from Continuing Operations figures came in at 105860000.0 (Q1 2026), 97044000.0 (Q4 2025), and 78359000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | -26.94 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -2.97 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 30.80 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | -3.40 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -14.46 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | -1.50 Mn |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 1.03 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -56.48 Mn |
| 10 | Praxis Precision Medicines | 200.22 Mn | -586.65 Mn | - | -105.86 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -105.86 Mn |
| Dec 31, 2025 | -97.04 Mn |
| Sep 30, 2025 | -78.36 Mn |
| Jun 30, 2025 | -76.07 Mn |
| Mar 31, 2025 | -74.73 Mn |
| Dec 31, 2024 | -63.96 Mn |
| Sep 30, 2024 | -56.84 Mn |
| Jun 30, 2024 | -37.49 Mn |
| Mar 31, 2024 | -41.89 Mn |
| Dec 31, 2023 | -27.81 Mn |
| Sep 30, 2023 | -25.52 Mn |
| Jun 30, 2023 | -34.96 Mn |
| Mar 31, 2023 | -38.09 Mn |
| Dec 31, 2022 | -41.45 Mn |
| Sep 30, 2022 | -43.95 Mn |
| Jun 30, 2022 | -60.39 Mn |
| Mar 31, 2022 | -68.85 Mn |
| Dec 31, 2021 | -58.58 Mn |
| Sep 30, 2021 | -44.71 Mn |
| Jun 30, 2021 | -36.40 Mn |